Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Buy” from the six research firms that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $30.60.

KURA has been the topic of a number of recent research reports. Stifel Nicolaus reduced their price target on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BVF Inc. IL grew its holdings in shares of Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after purchasing an additional 642,245 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Kura Oncology in the first quarter worth $507,000. Hennion & Walsh Asset Management Inc. lifted its stake in Kura Oncology by 42.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock worth $3,875,000 after acquiring an additional 54,031 shares during the period. Assenagon Asset Management S.A. lifted its stake in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the period.

Kura Oncology Trading Down 0.6 %

Shares of KURA opened at $20.95 on Friday. The firm’s 50 day simple moving average is $20.25 and its 200 day simple moving average is $20.63. The company has a market capitalization of $1.60 billion, a P/E ratio of -9.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. Kura Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.53) earnings per share. Sell-side analysts forecast that Kura Oncology will post -2.45 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.